Clevidipine Butyrate

Clevidipine is a dihydropyridine L-type calcium channel blocker, highly selective for vascular, as opposed to myocardial, smooth muscle and, therefore, has little or no effect on myocardial contractility or cardiac conduction. It reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure, confirming lack of effects on the venous capacitance vessels. No increase in myocardial lactate production in coronary sinus blood has been seen, confirming the absence of myocardial ischemia due to coronary steal.

Properties:
Appearance & Physical State: Powder
Density: 1.289g/cm3
Boiling Point: 539.7ºC at 760mmHg
Flash Point: 280.2ºC

Calcium Channel Inhibitors Related Products:

Manidipine 2HCl; Felodipine; Nisoldipine; Fasudil HCl; Cilnidipine; Dronedarone HCl; Efonidipine; Amlodipine; ISX-9 (Isoxazole 9); Gabapentin; MRS 1845; Fantofarone; Suvecaltamide (MK-8998); Ziconotide; Catharanthine Tartrate; Bepridil hydrochloride

[1]. Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.

[2]. Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.

[3]. Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.